CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

BACKGROUND: In clinical applications of CAR T-cell therapy, life-threatening adverse events including cytokine release syndrome and neurotoxicity can lead to treatment failure. Outcomes of patients treated with anti-CD30 CAR T- cell have been disappointing in relapsing/refractory (r/r) classical Hod...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Oncol
Asıl Yazarlar: Xue, YuanBo, Lai, Xun, Li, RuiLei, Ge, ChunLei, Zeng, BaoZhen, Li, Zhen, Fu, QiaoFen, Zhao, LiuFang, Dong, SuWei, Yang, JinYan, Guo, JiYin, Meng, QingYin, Tan, QingHua, Li, ZhenHui, Ding, HaiYan, Zhang, YanLei, Liu, ShaoHui, Chang, Alex H., Yao, Hong, Luo, RongCheng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Oncology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7885818/
https://ncbi.nlm.nih.gov/pubmed/33604290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.607362
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller